Modus Therapeutics Holding AB (publ) (STO:MODTX)
Sweden
· Delayed Price · Currency is SEK 0.289
-0.002 (-0.69%)
At close: Mar 6, 2026
Modus Therapeutics Holding AB Company Description
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden.
It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation.
Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB (publ)
| Country | Sweden |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | John Öhd |
Contact Details
Address: Olof Palmes gata 29 IV Stockholm, 11122 Sweden | |
| Phone | 46 8 50 13 70 00 |
| Website | modustx.com |
Stock Details
| Ticker Symbol | MODTX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015987904 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Öhd M.D., Ph.D. | Chief Executive Officer |
| Claes Lindblad | Chief Financial Officer and Head of IR |